Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

Phase 2icovamenibPositive

AI Analysis

Summary

Biomea Fusion announced completion of enrollment in the COVALENT-211 Phase II trial evaluating icovamenib in patients with insulin-deficient Type 2 Diabetes inadequately controlled on standard therapies.

Clinical Trial Data

Phase

Phase II

Outcome Details

Enrollment completed in COVALENT-211 Phase II trial

Importance:5/10

Sentiment:

0.30

diabetesPhase IIenrollment completeicovamenibCOVALENT-211

Related Companies

$BMEA

Read the original article

Published by GlobeNewswire Pharma on August 24, 2026 11:00 AM

Read Original